

Cover Story
Regulatory News
In a 14:1 vote, ODAC nixes a PD-1 drug developed in China; data not generalizable to U.S. population
By Paul Goldberg and Alice Tracey
The FDA Oncologic Drugs Advisory Committee expressed decisive support for the agency’s view that data from trials of checkpoint inhibitors performed in mainland China aren’t applicable to the U.S. population.
White House
By Matthew Bin Han Ong
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”